MX2015006109A - Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. - Google Patents

Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.

Info

Publication number
MX2015006109A
MX2015006109A MX2015006109A MX2015006109A MX2015006109A MX 2015006109 A MX2015006109 A MX 2015006109A MX 2015006109 A MX2015006109 A MX 2015006109A MX 2015006109 A MX2015006109 A MX 2015006109A MX 2015006109 A MX2015006109 A MX 2015006109A
Authority
MX
Mexico
Prior art keywords
treatment
cells
diseases caused
conjugated
express psma
Prior art date
Application number
MX2015006109A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Paul Leamon
Lontcho Rodoslavov Vlahov
Joseph Anand Reddy
Alicia Bloomfield
Ryan Dorton
Melissa Nelson
Marilynn Vetzel
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of MX2015006109A publication Critical patent/MX2015006109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015006109A 2012-11-15 2013-11-14 Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. MX2015006109A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261726991P 2012-11-15 2012-11-15
US201361788382P 2013-03-15 2013-03-15
US201361875971P 2013-09-10 2013-09-10
PCT/US2013/070007 WO2014078484A1 (en) 2012-11-15 2013-11-14 Conjugates for treating diseases caused by psma expressing cells

Publications (1)

Publication Number Publication Date
MX2015006109A true MX2015006109A (es) 2016-02-05

Family

ID=50731670

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006109A MX2015006109A (es) 2012-11-15 2013-11-14 Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
MX2021003858A MX2021003858A (es) 2012-11-15 2015-05-14 Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003858A MX2021003858A (es) 2012-11-15 2015-05-14 Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.

Country Status (17)

Country Link
US (17) US9636413B2 (enExample)
EP (3) EP3875082A1 (enExample)
JP (4) JP6892218B2 (enExample)
KR (5) KR102318999B1 (enExample)
CN (2) CN104797247A (enExample)
AU (10) AU2013344778C1 (enExample)
BR (1) BR112015011118B1 (enExample)
CA (3) CA2891476C (enExample)
EA (2) EA201890915A1 (enExample)
HK (2) HK1211493A1 (enExample)
IL (1) IL238784A0 (enExample)
MX (2) MX2015006109A (enExample)
MY (1) MY171561A (enExample)
SG (2) SG11201503303TA (enExample)
TW (1) TWI674111B (enExample)
WO (1) WO2014078484A1 (enExample)
ZA (1) ZA201504234B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652671A (en) 1994-06-30 1997-07-29 Texas Instruments Incorporated Hinge for micro-mechanical device
CA2149952A1 (en) 1994-06-30 1995-12-31 Robert M. Wallace Monolayer coating using molecular recognition for micro-mechanical devices
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3265471A1 (en) * 2015-03-01 2018-01-10 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
WO2017205447A1 (en) * 2016-05-24 2017-11-30 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
FI127538B (en) * 2016-06-22 2018-08-31 Dextech Medical Ab MODIFIED Dextran Conjugates
WO2018013930A1 (en) * 2016-07-14 2018-01-18 William Marsh Rice University Mechanical opening of lipid bilayers by molecular nanomachines
WO2019057964A1 (en) * 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh AMANITINE CONJUGATES TARGETING PSMA
DK3498308T3 (da) 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid
KR102156385B1 (ko) * 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
JP7546574B2 (ja) * 2019-01-30 2024-09-06 コヒレント バイオファーマ （スーチョウ），リミテッド 二重リガンド薬物コンジュゲート及びその使用
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2020252598A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
US20230097381A1 (en) * 2020-04-24 2023-03-30 Radiomedix, Inc. Composition, kit and method for diagnosis and treatment of prostate cancer
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
TW202430150A (zh) 2022-11-17 2024-08-01 德商溫瑟克斯製藥公司 在腫瘤微環境中可裂解之小分子藥物結合物
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
EP0116208B1 (en) 1982-12-07 1988-03-30 Kyowa Hakko Kogyo Co., Ltd. Mitomycin analogues
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5103018A (en) 1986-08-26 1992-04-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
KR20060025233A (ko) 1996-04-01 2006-03-20 에픽스 메디칼, 인코포레이티드 생체활성화 진단용 영상 콘트라스트 제제
JP2000508171A (ja) 1996-04-05 2000-07-04 ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 希少細胞の富化方法
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
EP1036093A1 (en) 1997-12-02 2000-09-20 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU2896399A (en) 1998-03-03 1999-09-20 Exact Sciences Corporation Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2002224401B2 (en) 2000-10-16 2007-12-06 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
CA2436408A1 (en) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
DE60232244D1 (de) 2001-06-21 2009-06-18 Glycomimetics Inc Nachweis und behandlung von prostatakrebs
US20030031677A1 (en) 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
EP2518142B1 (en) 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE60234782D1 (de) 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
DE60329274D1 (de) 2002-01-10 2009-10-29 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CN1650033A (zh) 2002-03-07 2005-08-03 约翰霍普金斯大学医学院 针对与癌症相关的表观遗传学沉默基因的基因组筛选
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
ES2438008T3 (es) 2002-05-06 2014-01-15 Endocyte, Inc. Agentes de formación de imágenes dirigidos a vitaminas
KR20040106547A (ko) 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7749968B2 (en) 2002-08-05 2010-07-06 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
WO2004015086A2 (en) 2002-08-08 2004-02-19 Johns Hopkins University Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
WO2004058158A2 (en) 2002-12-20 2004-07-15 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
EP1603392A2 (en) 2003-03-07 2005-12-14 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP4937751B2 (ja) 2003-06-13 2012-05-23 イミューノメディクス、インコーポレイテッド Ｄ−アミノ酸ペプチド
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1610818A4 (en) 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
US20070254317A1 (en) 2004-03-03 2007-11-01 Biomerieux Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate
ATE403157T1 (de) 2004-03-15 2008-08-15 Hoffmann La Roche Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
WO2005111238A2 (en) 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
EP1756166A4 (en) 2004-04-19 2008-08-27 Proscan Rx Pharma DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
MX2007002410A (es) 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
US7713944B2 (en) * 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
US7638525B2 (en) 2004-10-27 2009-12-29 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
US8606349B2 (en) 2004-11-09 2013-12-10 Biosensors International Group, Ltd. Radioimaging using low dose isotope
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
EP1844351A4 (en) 2005-01-13 2017-07-05 Biosensors International Group, Ltd. Multi-dimensional image reconstruction and analysis for expert-system diagnosis
WO2006083986A2 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
AU2006220621A1 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
AU2006262231B2 (en) 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
EP1909853B1 (en) 2005-07-19 2015-03-18 Biosensors International Group, Ltd. Imaging protocols
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
JP2009512423A (ja) 2005-09-12 2009-03-26 ザ・ジョンズ・ホプキンス・ユニバーシティ 抗血管新生の活性を有する組成物及びその使用
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US20070134332A1 (en) 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
CN104090095B (zh) 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
PL1999136T3 (pl) 2006-03-14 2013-03-29 Cancer Targeted Tech Llc Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
EP2046658A4 (en) * 2006-07-31 2009-11-04 Bayer Consumer Care Ag TWO-PIECE CONTAINER WITH AN ADJUSTABLE OPERATOR FOR A CUTTING DEVICE
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
ES2684322T3 (es) 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
US20100210792A1 (en) 2006-12-05 2010-08-19 David Taft Drug delivery
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN101568352B (zh) 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP2155231B1 (en) 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
WO2009002529A2 (en) 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
CN101784564B (zh) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-dc变体
EP2178896A1 (en) 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
WO2009035942A1 (en) 2007-09-13 2009-03-19 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US8507455B2 (en) 2007-12-04 2013-08-13 Alnylam Pharmaceuticals, Inc. Folate conjugates
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
CA2711678A1 (en) 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
HRP20151367T1 (hr) 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
AU2009268923B2 (en) * 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
ES2634894T3 (es) 2008-08-01 2017-09-29 The Johns Hopkins University Agentes de unión a PSMA y usos de los mismos
WO2010027641A2 (en) 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
EP2326350B1 (en) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP5675619B2 (ja) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
AU2009322167B2 (en) 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
US20120128587A1 (en) 2009-07-31 2012-05-24 Endocyte, Inc. Folate-targeted diagnostics and treatment
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
US9687572B2 (en) 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
HK1217085A1 (zh) 2012-12-28 2016-12-23 Tarveda Therapeutics, Inc 包封在顆粒中的靶向綴合物及其製劑
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
ES2743482T3 (es) 2014-05-06 2020-02-19 Univ Johns Hopkins Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
US10112974B2 (en) 2014-08-24 2018-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用

Also Published As

Publication number Publication date
AU2025204626A1 (en) 2025-07-10
AU2026203967A1 (en) 2026-06-11
US20160361432A1 (en) 2016-12-15
HK1255308A1 (zh) 2019-08-16
US20160361376A1 (en) 2016-12-15
AU2026204205A1 (en) 2026-06-18
AU2022201341A1 (en) 2022-03-24
AU2026204215A1 (en) 2026-06-18
BR112015011118B1 (pt) 2022-12-13
ZA201504234B (en) 2016-11-30
US20220265841A1 (en) 2022-08-25
SG11201503303TA (en) 2015-06-29
KR102575825B1 (ko) 2023-09-06
KR102354613B1 (ko) 2022-01-21
CN108042811A (zh) 2018-05-18
US20150297735A1 (en) 2015-10-22
KR20150104092A (ko) 2015-09-14
AU2013344778A1 (en) 2015-05-21
JP2016506372A (ja) 2016-03-03
CN104797247A (zh) 2015-07-22
AU2013344778C1 (en) 2024-06-27
EP3858341A1 (en) 2021-08-04
US20180256736A1 (en) 2018-09-13
US10912840B2 (en) 2021-02-09
JP2019081778A (ja) 2019-05-30
EP2919774A4 (en) 2016-11-09
SG10201706618UA (en) 2017-09-28
US20210154312A1 (en) 2021-05-27
US20180271991A1 (en) 2018-09-27
US20160361433A1 (en) 2016-12-15
US20210154311A1 (en) 2021-05-27
US20190314515A1 (en) 2019-10-17
HK1211493A1 (en) 2016-05-27
TW201420119A (zh) 2014-06-01
WO2014078484A1 (en) 2014-05-22
JP6892218B2 (ja) 2021-06-23
AU2020202904B2 (en) 2022-02-24
EP2919774A1 (en) 2015-09-23
US20170258932A1 (en) 2017-09-14
KR102499944B1 (ko) 2023-02-14
AU2025204626B2 (en) 2025-08-28
AU2020202904A1 (en) 2020-05-21
AU2020201329C1 (en) 2024-05-09
KR20220013456A (ko) 2022-02-04
US9636413B2 (en) 2017-05-02
MX2021003858A (es) 2021-04-28
AU2018204504A1 (en) 2018-07-12
EP3875082A1 (en) 2021-09-08
CA3158675A1 (en) 2014-05-22
TWI674111B (zh) 2019-10-11
CA2891476A1 (en) 2014-05-22
IL238784A0 (en) 2015-06-30
US20250170253A1 (en) 2025-05-29
US20180289826A1 (en) 2018-10-11
KR102318999B1 (ko) 2021-10-29
US20180256737A1 (en) 2018-09-13
CA2891476C (en) 2022-07-05
KR20230025942A (ko) 2023-02-23
EA201890915A1 (ru) 2018-09-28
JP2021073272A (ja) 2021-05-13
US9782493B2 (en) 2017-10-10
US20180256734A1 (en) 2018-09-13
AU2020201329B2 (en) 2022-02-24
KR20210041633A (ko) 2021-04-15
EA201590783A1 (ru) 2015-11-30
JP2023098946A (ja) 2023-07-11
AU2024203858A1 (en) 2024-06-27
US20180256733A1 (en) 2018-09-13
CA3306064A1 (en) 2026-05-13
US20180256735A1 (en) 2018-09-13
AU2020201329A1 (en) 2020-03-12
AU2013344778B2 (en) 2018-03-22
KR20210041632A (ko) 2021-04-15
MY171561A (en) 2019-10-18
BR112015011118A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
PY1212975A (es) Compuestos de azabiclo o quinuclidin-carbamato como inhibidores de glucosilceramida sintasa
GT201500051A (es) Inhibidores de glucosilceramida sintasa
AR091837A1 (es) Compuestos para inmunoterapia dirigida
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
PH12014501702A1 (en) Imidazopyrrolidinone compounds
ECSP13012572A (es) Análogos de nucleótidos sustituidos
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201590115A1 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
ECSP15004005A (es) Jeringa
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
EA201400178A1 (ru) Лечение рака молочной железы
MY168032A (en) Warm-Cool Beauty Treatment Device
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112013024211A2 (pt) tratamento de tumores sólidos
MX359769B (es) Metodos para descelularizar huesos.
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MY166103A (en) Disposable diaper
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PT2831110T (pt) Terapia anti-emp2 reduz as células-tronco do cancro
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
UY34286A (es) Diagnóstico de vacuna mejorado